GlassScriptPhysician profile
Martin Morell
NPI 1811990997
$47,012.00
in general payments reported to CMS, 2019-2025
37 companies · $3,343 in 2025
The $3,343 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $8,546 · 2021: $5,142 · 2022: $3,346 · 2023: $3,744 · 2024: $3,785 · 2025: $3,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,546.08 |
| Education | $326.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $19,669.13 | 2019-2023 | Krystexxa, Tepezza |
| Abbvie INC. | $9,212.45 | 2019-2025 | |
| Ucb, INC. | $3,407.49 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $3,234.54 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $2,091.42 | 2019-2025 | |
| Amgen INC. | $1,501.15 | 2019-2025 | Krystexxa, Uplizna, Amjevita |
| Novartis Pharmaceuticals Corporation | $1,481.20 | 2019-2025 | |
| Genentech USA, INC. | $1,131.79 | 2019-2025 | Actemra, Rituxan |
| E.R. Squibb & Sons, L.L.C. | $1,015.10 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $718.89 | 2021-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $448.22 | 2019-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $421.43 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.46 | 2022-2025 | Ofev, Cyltezo |
| Celgene Corporation | $329.88 | 2019 | |
| Lilly USA, LLC | $304.22 | 2019-2025 | Omvoh |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $244.34 | 2023-2025 | Idacio |
| Mallinckrodt Enterprises LLC | $229.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $175.17 | 2019-2023 | |
| Genentech, INC. | $143.85 | 2020 | |
| Sobi, INC | $122.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $111.75 | 2020-2023 | Benlysta |
| Genzyme Corporation | $104.57 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $89.45 | 2022-2023 | Lupkynis |
| Merck Sharp & Dohme LLC | $72.19 | 2020-2021 | |
| Tactile Systems Technology INC | $64.54 | 2025 | Flexitouch Plus, Nimbl |
| Pacira Therapeutics, INC. | $47.82 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $47.11 | 2023-2024 | Truxima |
| Organon LLC | $46.07 | 2023-2025 | Hadlima, Renflexis |
| Octapharma USA, INC. | $34.17 | 2022 | |
| Tonix Medicines, INC. | $29.82 | 2025 | Tonmya |
| Fidia Pharma USA INC. | $29.28 | 2024-2025 | Hymovis, Triluron, Hyalgan |
| Bioventus LLC | $20.71 | 2024 | Supartz Fx Sodium Hyaluronate |
| Ars Pharmaceuticals Operations, INC. | $20.13 | 2025 | Neffy |
| Ani Pharmaceuticals, INC. | $20.12 | 2025 | Purified Cortrophin Gel |
| Depuy Synthes Sales INC. | $19.36 | 2025 | Orthovisc, Monovisc, Peak |
| Celltrion USA INC. | $17.54 | 2023 | Yuflyma |
| Sandoz INC. | $14.72 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Morell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.